NxStage Medical (NXTM) Receiving Somewhat Positive News Coverage, Analysis Finds
Media headlines about NxStage Medical (NASDAQ:NXTM) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. NxStage Medical earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 45.1911998459261 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Head-To-Head Analysis: Analogic Corporation (ALOG) versus NxStage Medical (NXTM) (americanbankingnews.com)
- NxStage Medical, Inc. (NASDAQ:NXTM) Stock Traded Significantly Above Its 50 Day Average (highlightpress.com)
- NxStage Medical : U.S. Patents Awarded to Inventors in Utah (July 15) (4-traders.com)
- Reviewing Analogic Corporation (ALOG) and NxStage Medical (NASDAQ:NXTM) (americanbankingnews.com)
- ETFs with exposure to NxStage Medical, Inc. : July 13, 2017 (finance.yahoo.com)
NxStage Medical (NXTM) traded down 0.12% during midday trading on Tuesday, reaching $24.35. 284,627 shares of the company’s stock traded hands. The firm’s market cap is $1.60 billion. The firm’s 50-day moving average is $22.79 and its 200 day moving average is $26.13. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80.
NxStage Medical (NASDAQ:NXTM) last issued its earnings results on Tuesday, May 9th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. The firm had revenue of $96.83 million for the quarter, compared to the consensus estimate of $95.31 million. NxStage Medical had a negative net margin of 1.25% and a negative return on equity of 2.31%. The business’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.02) earnings per share. Equities research analysts expect that NxStage Medical will post ($0.03) earnings per share for the current fiscal year.
Several equities research analysts have commented on NXTM shares. Canaccord Genuity reiterated a “buy” rating and issued a $32.00 price objective on shares of NxStage Medical in a research note on Monday, May 8th. Northland Securities reiterated a “buy” rating and issued a $35.00 price objective on shares of NxStage Medical in a research note on Monday, April 3rd. Jefferies Group LLC decreased their price objective on shares of NxStage Medical from $38.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, May 10th. Craig Hallum started coverage on shares of NxStage Medical in a research note on Tuesday, June 27th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, BTIG Research reiterated a “buy” rating and issued a $27.00 price objective on shares of NxStage Medical in a research note on Wednesday, May 10th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. NxStage Medical has an average rating of “Buy” and an average target price of $30.50.
In related news, CEO Jeffrey H. Burbank sold 3,000 shares of the stock in a transaction that occurred on Thursday, April 20th. The shares were sold at an average price of $27.28, for a total transaction of $81,840.00. Following the transaction, the chief executive officer now owns 939,086 shares in the company, valued at $25,618,266.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Matthew W. Towse sold 4,300 shares of the stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $21.36, for a total transaction of $91,848.00. Following the transaction, the senior vice president now owns 29,637 shares in the company, valued at approximately $633,046.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,150 shares of company stock worth $713,647. Insiders own 4.70% of the company’s stock.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.